Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Open-label Study of Abexinostat in Relapsed or Refractory Follicular Lymphoma
2018-001701-82Phase 2Terminated
- Sponsor
- Xynomic Pharmaceuticals
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of abexinostat in follicular lymphoma (FL), sponsored by Xynomic Pharmaceuticals. Primary endpoint: Objective response rate. Started Jan 2019; status: terminated.
02
Drugs
abexinostat
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2018-001701-82.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001701-82.